IL6 and congenital rubella syndrome: Tocilizumab is an IL-6 inhibitor that has been FDA approved for chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome (CRS) and has shown promise in the treatment of COVID-19 associated acute coronary syndrome [12, 13].